Related Experiment Video
Updated: Mar 7, 2026
05:37
Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration
Published on: May 31, 2018
12.8K
Effect of Age on Liver Function in Patients Undergoing Partial Hepatectomy
T M Lodewick1, P H Alizai, R M van Dam
1Department of General, Visceral and Transplantation Surgery, RWTH University Hospital Aachen, Aachen, Germany.
Digestive Surgery
|February 15, 2017
Summary
This study found no significant difference in preoperative liver function between patients under 60 and over 70 years old undergoing liver resection. Age does not appear to impact liver function before surgery.
Area of Science:
- Hepatobiliary Surgery
- Geriatric Medicine
- Surgical Oncology
Background:
- Postresectional liver failure is a significant cause of mortality after liver surgery.
- Preoperative liver function may decline with age, potentially increasing surgical risk in elderly patients.
- Evaluating age-related differences in liver function is crucial for optimizing surgical outcomes.
Purpose of the Study:
- To assess and compare preoperative liver function in patients younger than 60 years versus those older than 70 years scheduled for liver resection.
- To determine if advanced age is associated with diminished liver function prior to liver surgery.
- To inform surgical decision-making and risk stratification in liver resection candidates.
Main Methods:
- Prospective inclusion of consecutive patients aged <60 or >70 years undergoing elective liver surgery (2011-2013).
- Preoperative liver function assessed using the methacetin breath liver function test (LiMAx).
- Correlation between patient age and LiMAx values analyzed using Pearson's test; background liver disease evaluated via histology.
Main Results:
- Fifty-nine patients were analyzed (31 <60 years, 28 >70 years).
- No significant differences in general patient characteristics or LiMAx values were observed between the age groups (p = 0.699).
- No correlation was found between patient age and preoperative liver function (LiMAx values, R = 0.04, p = 0.810).
Conclusions:
- Preoperative liver function, as measured by LiMAx, does not appear to differ significantly between younger (<60 years) and older (>70 years) patients.
- Advanced age alone may not be a predictor of diminished liver function in patients undergoing liver resection.
- These findings suggest that age stratification alone may not be sufficient for predicting liver function in surgical candidates.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
245
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
245
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
304
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
304
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
285
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
285
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
319
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
319
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
294
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
294
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
273
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
273